Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( "Compass" ) CMPX, a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public ...
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
BOSTON, Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( "Compass" ) ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten ...
Compass Therapeutics Posts Wider Q2 Loss
Compass Therapeutics ( NASDAQ:CMPX ) , a clinical-stage biotechnology company focused on developing novel bispecific antibody therapies for cancer, released its second quarter results on August 11, 2025. The company reported a net loss per share of $ ( 0.14 ) ( GAAP ) in the second quarter, ...
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
BOSTON, May 08, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported first quarter 2025 financial results and provided a business update.
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research ( AACR ) Annual Meeting
BOSTON, April 28, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled "Enhanced Efficacy of CTX-471, A CD137 ...
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
BOSTON, April 21, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial ( IST ) to ...
Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer - Compass Therapeutics ( NASDAQ:CMPX )
Tovecimig plus paclitaxel showed a 17.1% overall response rate in BTC patients, significantly higher than 5.3% for paclitaxel alone ( p=0.031 Progressive disease rates were 16.2% for tovecimig plus paclitaxel versus 42.1% for paclitaxel alone, indicating improved disease control.
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Beta Bionics ( NASDAQ:BBNX ) , Compass Therapeutics ( NASDAQ:CMPX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Barclays analyst Benjamin Budish initiated coverage on Blue Owl Capital Inc.
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Candel Therapeutics ( NASDAQ:CADL ) , Compass Therapeutics ( NASDAQ:CMPX )
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. CICC analyst Lin Wang initiated coverage on GE Vernova Inc. GEV with an Outperform rating.
Compass Therapeutics, Inc. ( CMPX ) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc.
Is Compass Therapeutics, Inc. ( CMPX ) Stock Outpacing Its Medical Peers This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper ...
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. CMPX, a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Piper Sandler 36th ...
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. ( CMPX )
Compass Therapeutics, Inc. (CMPX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock ...
What Makes Compass Therapeutics, Inc. ( CMPX ) a New Buy Stock
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the ...
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer ( SITC ) Annual Meeting
BOSTON, Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled "Pharmacodynamic and Response Biomarkers in ...
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, Oct. 04, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc.
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BOSTON, Oct. 04, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster ...
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Sept. 03, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the ...
Eliem Therapeutics Announces Additions to its Leadership Team
Brett Kaplan, M.D. appointed Chief Operating Officer ...
Eliem Therapeutics Announces Additions to its Leadership Team - Eliem Therapeutics ( NASDAQ:ELYM )
SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 ( GLOBE NEWSWIRE ) -- Eliem Therapeutics, Inc. ELYM, announced today the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development.
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, Aug. 07, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc.
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 07, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush ...
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer - Compass Therapeutics ( NASDAQ:CMPX )
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic or Recurrent Biliary Tract Cancers ( BTC )
Compass Therapeutics, Inc. ( CMPX ) Upgraded to Buy: Here's Why
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics Announces CEO Transition - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, May 28, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc.
Compass Therapeutics Announces CEO Transition
BOSTON, May 28, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed ...
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology ( ASCO ) Annual Meeting 2024
BOSTON, May 23, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced an upcoming poster presentation of its novel ...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, April 12, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc.
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
BOSTON, April 12, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the ...
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research ( AACR ) Annual Meeting
BOSTON, April 09, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today presents a poster on the combination of its ...
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
• Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 ( DLL4 x VEGF-A bispecific antibody ) in patients with advanced biliary tract cancer ( BTC ) , continues to progress well.
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc.
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial - Compass Therapeutics ( NASDAQ:CMPX )
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface PD-1
Compass Therapeutics, Inc. ( CMPX ) Upgraded to Buy: Here's What You Should Know
Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compass Therapeutics Provides Corporate Update
BOSTON, Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
Compass Therapeutics, Inc. ( CMPX ) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Compass Therapeutics, Inc. (CMPX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a ...
Why NextGen Healthcare Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Addex Therapeutics ( NASDAQ:ADXN ) , Aditxt ( NASDAQ:ADTX )
Helius Medical Technologies, Inc. HSDT rose 65.3% to $12.20 in pre-market trading after gaining around 9% on Friday. Crown ElectroKinetics Corp. CRKN shares gained 47.1% to $1.75 in pre-market trading. Crown Electrokinetics is scheduled to hold an investor update conference call on Sept. 18, 2023.
Compass Therapeutics to Participate in Upcoming Investor Events
BOSTON, Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the ...
Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring
Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed ... PR ...
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
BOSTON, June 22, 2023 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000® ...
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes - Compass Therapeutics ( NASDAQ:CMPX )
BOSTON, June 22, 2023 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc.
Monoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
Monoclonal Antibodies Clinical Trial Experiences Momentum ... PR ...
Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium
BOSTON, March 28, 2023 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the ...
Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
BOSTON, March 15, 2023 ( GLOBE NEWSWIRE ) -- Compass Therapeutics, Inc. ( Nasdaq: CMPX ) , a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported fourth quarter and full year 2022 financial ...
Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.31% to 33,524.12 while the NASDAQ fell 0.11% to 11,352.46. The S&P 500 also fell, dropping, 0.30% to 4,007.66.
Compass Therapeutics' Combo Therapy Shows Around 38% Overall Response Rate In Pretreated Biliary Tract Cancer Patients
Compass Therapeutics Inc CMPX announced the presentation of data from a Phase 2 study of CTX-009 in combination with paclitaxel in patients with biliary tract cancers ( BTC ) .
